29 completed, 17 recruiting, 10 active not recruiting, 10 unknown. 53 Phase 2, 20 Phase 1, 7 Not applicable, 1 Early Phase 1.
Follow this condition Literature Review of Carcinoma, Adenoid Cystic trials Research Report on Carcinoma, Adenoid Cystic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Actuate Therapeutics Inc. | 2030-12-18 | 2022-02-22 | |
| Phase II Trial Comparing Stereotactic Body Radiotherapy Versus Active Surveillance for Oligometastatic Adenoid Cystic Carcinoma Stereotactic body radiotherapy (SBRT) - Adenoid Cystic Carcinoma, Oligometastatic | Phase 2 | Not yet recruiting | All India Institute of Medical Sciences | 90 | 2026-12-20 | 2026-09-28 |
| Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP) Sacituzumab Tirumotecan - Recurrent Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma Metastatic | Phase 2 | Not yet recruiting | National Cancer Centre, Singapore | 68 | 2026-11-01 | 2026-07-15 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-10-26 | 2026-10-21 |
| Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma Anlotinib + Epirubicin - Adenoid Cystic Carcinoma | Phase 2 | Not yet recruiting | Eye & ENT Hospital of Fudan University | 76 | 2026-06-01 | 2026-06-01 |
| Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma: A Prospective Observational Study Surgery - Adenoid Cystic Carcinoma, Sinonasal Carcinoma | Recruiting | Eye & ENT Hospital of Fudan University | 70 | 2026-06-01 | 2026-06-17 | |
| SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma Postoperative Radiotherapy, Observation - Adenoid Cystic Carcinoma, Sinonasal Carcinoma | Not yet recruiting | Eye & ENT Hospital of Fudan University | 200 | 2026-05-01 | 2026-05-12 | |
| Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I) P-Sam - Adenoid Cystic Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 28 | 2026-04-29 | 2026-09-21 |
| A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma Becotatug Vedotin - Adenoid Cystic Carcinoma, Sinonasal Carcinoma | Phase 2 | Recruiting | Eye & ENT Hospital of Fudan University | 40 | 2026-04-28 | 2026-07-28 |
| Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study Epirubicin (E) - Adenoid Cystic Carcinoma, Sinonasal Carcinoma | Phase 2 | Recruiting | Eye & ENT Hospital of Fudan University | 100 | 2026-01-20 | 2026-05-12 |
| Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE Questionnaire - Cancer, Cystic Carcinomas, Adenoid | Completed | Hospices Civils de Lyon | 62 | 2025-05-23 | 2025-08-06 | |
| A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma Enfortumab Vedotin - Adenoid Cystic Carcinoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 34 | 2025-03-31 | 2026-10-01 |
| A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers Ivonescimab - Salivary Gland Cancer, Advanced Salivary Gland Carcinoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 35 | 2025-02-26 | 2026-10-21 |
| 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma 177Lu-PNT2002 - Adenoid Cystic Carcinoma | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 | 2025-02-10 | 2026-01-22 |
| A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit NN3201 - Gastrointestinal Stromal Tumors, Small-cell Lung Cancer | Phase 1 | Recruiting | Novelty Nobility, Inc. | 67 | 2025-02-03 | 2025-09-23 |
| Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma HG146 - Adenoid Cystic Carcinoma, Head and Neck Cancer | Phase 2 | Recruiting | HitGen Inc. | 140 | 2024-12-13 | 2026-09-21 |
| Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) RGT-61159, lenvatinib - Adenoid Cystic Carcinoma, Colorectal Cancer | Phase 1 | Active not recruiting | Rgenta Therapeutics Inc | 105 | 2024-08-19 | 2026-09-17 |
| An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma Computed Tomography, Electronic Health Record Review, Ga-68 PSMA-11 - Metastatic Adenoid Cystic Carcinoma | Phase 2 | Completed | Mayo Clinic | 6 | 2024-08-12 | 2025-09-12 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial Lutetium (177Lu) vipivotide tetraxetan - Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Maria Sklodowska-Curie National Research Institute of Oncology | 2024-01-01 | 2025-02-10 |
Showing 20 of 79. Sign in to see all of them.
Salivary Gland Neoplasms (18) · Head and Neck Neoplasms (7) · Neoplasm Metastasis (7) · Melanoma (6) · Neoplasms (6) · Breast Neoplasms (5) · Colorectal Neoplasms (5) · Osteosarcoma (5) · Sarcoma (5) · Adenocarcinoma (4) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Renal Cell (4) · Cholangiocarcinoma (4) · Chordoma (4)
Neoplasms by Histologic Type (78) · Neoplasms, Glandular and Epithelial (78) · Carcinoma (77) · Adenocarcinoma (75) · Neoplasms (73) · Neoplasms by Site (37) · Head and Neck Neoplasms (21) · Mouth Diseases (19) · Stomatognathic Diseases (19) · Mouth Neoplasms (18) · Salivary Gland Diseases (18) · Digestive System Diseases (12) · Digestive System Neoplasms (12) · Neoplasms, Germ Cell and Embryonal (12) · Pathological Conditions, Signs and Symptoms (12)
pembrolizumab (8) · lenvatinib (4) · Carboplatin (3) · Imatinib Mesylate (3) · Magnetic Resonance Spectroscopy (3) · apatinib (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (2) · Axitinib (2) · Cisplatin (2) · Epirubicin (2) · Nivolumab (2) · Protons (2) · Radiosurgery (2) · Specimen Handling (2)
Memorial Sloan Kettering Cancer Center (6) · Eye & ENT Hospital of Fudan University (5) · Dana-Farber Cancer Institute (4) · M.D. Anderson Cancer Center (4) · Radboud University Medical Center (3) · Ayala Pharmaceuticals, Inc, (2) · Heidelberg University (2) · Hospices Civils de Lyon (2) · Mayo Clinic (2) · National Cancer Centre, Singapore (2) · National Cancer Institute (NCI) (2) · Peking Union Medical College Hospital (2) · Seoul National University Hospital (2) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (2) · Actuate Therapeutics Inc. (1)
United States (44) · China (13) · France (9) · Canada (5) · Germany (5) · Netherlands (5) · South Korea (5) · Spain (3) · Australia (2) · Singapore (2) · United Kingdom (2) · Austria (1) · Brazil (1) · Guam (1) · Israel (1)
Alan Ho, MD, PhD (4) · Carla ML van Herpen, MD, PhD (2) · Glenn J Hanna, MD (2) · Renata Ferrarotto (2) · Renata Ferrarotto, MD (2) · Alan L. Ho, MD, PhD (1) · Ana Kiess, MD, PhD (1) · Annie W Chan, MD (1) · Ashish Chintakuntlawar, MBBS, PhD (1) · Athanassios E Argiris, MD (1) · Brian J. Burkett, MD, MPH (1) · Camila MV Moniz, Doctor (1) · Charalampos Floudas, M.D. (1) · Chenping Zhang, M.D. (1)
PMID 16757203, PMID 37097003, PMID 17960615, PMID 21612974, PMID 31463986, PMID 32629365, PMID 41089828, PMID 12112535, PMID 17761983, PMID 19451433, PMID 21320355, PMID 23747147, PMID 24033920, PMID 24596143, PMID 25362970, PMID 25456010, PMID 28551643, PMID 29149611, PMID 30447126, PMID 31586664, PMID 31650066, PMID 31969335, PMID 32781104, PMID 33362722, PMID 33882143, PMID 33995600, PMID 34266402, PMID 34380663, PMID 34503735, PMID 34716198, PMID 34920917, PMID 34927307, PMID 35606739, PMID 35984529, PMID 36319717, PMID 36734294, PMID 36898078, PMID 37294948, PMID 37643133, PMID 37703531, PMID 37939426, PMID 38118249, PMID 38243705, PMID 38358334, PMID 38539566, PMID 39067873, PMID 39097677, PMID 39343510, PMID 39417692, PMID 39563886
2008 (1), 2016 (1), 2023 (1), P01CA021239 (1), R44CA250824 (1), U10CA180888 (1)